Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Reexamination Certificate
1998-03-27
2001-12-25
Geist, Gary (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
C514S178000, C514S182000, C552S625000
Reexamination Certificate
active
06333317
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the treatment of various neurological diseases and neurodegenerative disorders associated with aging, particularly those affected by an overabundance of Amyloid Precursor Protein (APP). In particular, this invention relates to the APP holoprotein synthesis and the effect of lipophilic compounds on regulating the expression of this protein. In particular, it has been discovered that certain neurodegenerative or cognitive changes are associated with developing an imbalance in the serum levels of endogenous, gynecologically relevant substances, including certain neurotransmitters, neurotransmitter substrates or hormones. It has also been found that the level of APP holoprotein is reduced by lipophilic estrogenic compounds in brain cells, and that this reduction is expected to reduce the neurotoxicity or neurodegeneration associated with APP over expression.
BACKGROUND OF THE INVENTION
Alzheimer's Disease (AD) is the most common neurodegenerative disorder of aging, and is characterized by progressive dementia and personality dysfunction. The abnormal accumulation of amyloid plaques in the vicinity of degenerating neurons and reactive astrocytes is a pathological characteristic of AD.
Several lines of studies suggest that postmenopausal women with lower levels of endogenous estrogen may be predisposed to the development of AD. Studies in experimental animal models provide a convincing rational for the role of estrogen replacement therapy and prevention of dementia. See, for example, Birge,
J. Am. Geriatric. Soc
. 44, 865, (1996). These studies suggest that estrogen deficiency in postmenopausal women apparently increases their susceptibility to the neurodegenerative changes of aging and AD, and that this risk can be decreased by estrogenic replacement therapy. Peganini et al.
Am. J. Epidemiol
, 140, 256 (1994). Estrogen treatment of cell culture reportedly promotes non-amyloidogenic APP processing and soluble APP (APPs) secretion. Jaffe et al.,
J. Biol. Chem
. 269, 13065 (1994).
APP processing is regulated by neurotransmitters and synaptic activity. Amyloid plaques in AD accumulate near dystrophic neurons and reactive astrocytes. Cordell,
Annu. Rev. Pharmacol. Toxicol
. 34, 69 (1994); Selkoe, Annu. Rev. Neurosci. 17, 489 (1994). The activation of neurotransmitter receptors, which are coupled to phosphotidylinositol (PI) hydrolysis or to protein kinase C (PKC) activation, can promote APP metabolism and decrease amyloid formation. Nitsch, et al.,
Science
258, 304 (1992); Wolf et al.,
J. Biol. Chem
. 270, 4916 (1995); Buxbaum et al.,
Proc. Natl. Acad. Sci. U.S.A
. 91, 4489 (1994); Lee, et al., Ibid., 92, 8083 (1995); Ulus and Wurtman,
J. Pharm. Exp. Ther
., 281,149 (1997); Lee et al.,
Proc. Natl. Acad. Sci. U.S.A
. 92, 8083 (1995). Activation of neurotransmitters coupled to cAMP production suppresses both constitutive and PKC/PI-stimulated APPs secretion in astroglioma cells and in primary astrocytes. Eftimiopoulos et al.,
J. Neurochem
., 67, 872 (1996); Lee et al.,
J. Neurochem
., 68,1830 (1997). The drastic alterations in neurotransmitter levels and second messenger signaling created by neurodegeneration and synapse loss in AD may disrupt APP processing in ways that promote the accumulation of amyloidogenic or neurotoxic APP fragments.
Additionally, the loss of various neurotransmitters in AD may increase cellular levels of APP holoprotein containing amyloidogenic or neurotoxic peptides due to a decrease in proper APP metabolism. Yankner et al.,
Science
, 245, 417 (1989); M. R. Kozlowski, A. Spanoyannnis, S. P. Manly, S. A. Fidel, R. L. Neve,
J. Neurosci
, 12, 1679 (1992).
Increased APP production in Down's syndrome is associated with a high incidence of AD at an early age due to the extra copy of the APP gene. Over expression of APP in cell cultures and in transgenic mice is also associated with neurodegeneration and age-related cognitive deficits, suggesting that over expression of APP could contribute to the neuropathology of AD. Maruyama, et al.,
Nature
, 347, 566 (1990); Hsiao et al.,
Neuron
15, 1203-1218 (1995); Moran, et al.,
Proc. Natl. Acad Sci. U.S.A
. 92, 5341 (1995).
Several APP isoforms, ranging in size from 695-770 amino acids, are derived by differential splicing of a primary transcript of the three major APP isoforms, APP-695 is predominantly expressed in neurons; APP-751 and APP-770, which harbor an additional Kunitz-type protease inhibitor (KPI) insert at the N-terminus, are predominantly expressed in astrocytes and appear to be increased in AD brain. Golde, S. et al.,
Neuron
4, 253 (1990); Neve, et al.,Ibid., 1, 669 (1990); Anderson et al., EMBO J. 8, 3627 (1989); Nordstedt et al.,
Proc. Natl. Acad. Sci. U.S.A
. 88, 8910 (1991). The decreased amounts of APP-695 in postmortem AD brains may be due to neuronal loss. The increase in KPI-containing APP isoforms in AD and in regions surrounding senile plaques raises the possibility that APP overexpression in astrocytes contributes to AD neuropathology.
Several lines of studies have indicated an apparently low incidence of Alzheimer's Disease in rheumatoid arthritis patients. These studies propose the possibility that anti-inflammatory therapy with NSAIDs (non-steroidal anti-inflammatory drugs) confers some protection against AD. See, e.g., McGeer, et al.,
Lancet
, 335, 1037 (1990); Andersen, et al.,
Neurology
, 45, 1441 (1995); Rich, et al. Neurology, 45, 51 (1995); Lindsay, et al.,
Neurology
, 44, 2073 (1994); Rogers, et al.,
Neurology
, 43, 1609 (1993). These studies suggest that the administration of a non-steroidal anti-inflammatory drug may reduce the onset of dementia in Alzheimer's patients. However, none of these studies discloses or suggests that the administration of NSDAs prevents the overproduction of APP.
Persistent and rapid elevations in APP immunoreactivity have been observed in GFAP-positive astrocytes following brain injury. Siman et al.,
J. Neurosci
., 3, 275 (1989); Banati and Kreutzberg,
J. Cereb. Blood Flow Metab
., 12, 257 (1995). In the AD brain, the loss of synapses is associated with an increase in the number of GFAP-positive astrocytes (Brun et al.,
Neurodegeneration
, 4, 171 (1995), and increases in KPI containing APP mRNA in the frontal cortex have also been attributed to the astrocytic response during neuronal damage (Golde et al.,
Neuron
, 4, 253 (1990). It seems that the loss of synapses and neurons in AD might initiate a pathological cascade that includes APP overexpression by reactive astrocytes.
In U.S. Pat. No. 5,385,915, Buxbaum et al. describe methods and compositions for affecting APP processing by the administration of agents that regulate protein phosphorylation, namely agents that regulate kinases or phosphatases. The modulation of APP processing leads, in turn, to the regulation of the production of &bgr;/A
4
peptide, a peptide that accumulates in amyloidogenic plaques. See, e.g., col. 6, lines 8-10. Hence, Buxbaum et al. teach that one's objective should focus on the search for agents that alter the metabolism of APP.
However, Buxbaum et al. make no mention, teaching, or suggestion that the step preceding the processing of APP, that is, the expression, production, or formation of APP, itself, can be at all affected by select groups of substances. Indeed, as Buxbaum et al. state (at col. 21, lines 7-9), “the effects observed are attributable to changes in APP metabolism rather than APP transcription (emphasis added).” Consistent with this notion, the claims of Buxbaum et al. are drawn to a method of regulating phosphorylation of proteins that control the processing of APP.
Similarly, in U.S. Pat. No. 5,242,932, Gandy et al. disclose and claim a method of modulating or affecting the intracellular trafficking and processing of APP in the mammalian cell.
For additional background information on the processing of APP, release of APP derivatives, or the processing, degradation and secretion of &bgr;/A
4
APP, the interested reader is referred to
Lee Robert K. K.
Wurtman Richard J.
Crane L. E.
Geist Gary
Massachusettes Institute of Technology
Pepper Hamilton L.L.P.
Pouliquen Corinne M.
LandOfFree
Regulation of amyloid precursor protein (APP) expression by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of amyloid precursor protein (APP) expression by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of amyloid precursor protein (APP) expression by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2587784